Literature DB >> 3257303

Hormone conjugated with antibody to CD3 mediates cytotoxic T cell lysis of human melanoma cells.

M A Liu1, S R Nussbaum, H N Eisen.   

Abstract

Cytotoxic T lymphocytes can be activated by antibodies to their antigen-specific receptor complex (TCR-CD3) to destroy target cells, regardless of the specificity of the cytotoxic T cells. A novel hormone-antibody conjugate, consisting of an analog of melanocyte-stimulating hormone chemically coupled to a monoclonal antibody to CD3, the invariant component of the T cell receptor complex, was used to target human melanoma cells for destruction by human cytotoxic T lymphocytes that bear no specificity for the tumor cells. As targeting components of such anti-CD3 conjugates, hormones or growth factors are expected to prove more effective than antibodies to tumor-associated antigens in focusing the destructive activity of cytotoxic T cells on tumor target cells.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3257303     DOI: 10.1126/science.3257303

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  8 in total

Review 1.  Antibody mediated targeting of radioisotopes, drugs and toxins in diagnosis and treatment.

Authors:  C H Ford; V J Richardson; V S Reddy
Journal:  Indian J Pediatr       Date:  1990 Jan-Feb       Impact factor: 1.967

2.  Homologous recombination between transferred and chromosomal immunoglobulin kappa genes.

Authors:  M D Baker; M J Shulman
Journal:  Mol Cell Biol       Date:  1988-10       Impact factor: 4.272

3.  Chemically programmed bispecific antibodies that recruit and activate T cells.

Authors:  Huiting Cui; Joshua D Thomas; Terrence R Burke; Christoph Rader
Journal:  J Biol Chem       Date:  2012-07-03       Impact factor: 5.157

4.  Amelioration of experimental lung metastasis in mice by therapy with anti-CD3 monoclonal antibodies.

Authors:  D W Hoskin; J Stankova; S K Anderson; J C Roder
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

Review 5.  Human autologous tumor-specific T cells in malignant melanoma.

Authors:  C D Platsoucas
Journal:  Cancer Metastasis Rev       Date:  1991-06       Impact factor: 9.264

6.  Augmentation of interleukin-2-induced activation of human melanoma tumor-infiltrating lymphocytes by heteroconjugate antibody.

Authors:  P F Mansfield; M G Rosenblum; J L Murray; K Itoh
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

7.  Conjugates of folate and anti-T-cell-receptor antibodies specifically target folate-receptor-positive tumor cells for lysis.

Authors:  D M Kranz; T A Patrick; K E Brigle; M J Spinella; E J Roy
Journal:  Proc Natl Acad Sci U S A       Date:  1995-09-26       Impact factor: 11.205

8.  A chelating derivative of alpha-melanocyte stimulating hormone as a potential imaging agent for malignant melanoma.

Authors:  D R Bard; C G Knight; D P Page-Thomas
Journal:  Br J Cancer       Date:  1990-12       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.